# US 2003/0228360 A1 · Combination immediate release controlled release levodopa/carbidopa dosage forms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0228360 A1
- Document ID: US20030228360A1
- Status: Published application
- Kind: A1
- Application number: 10/241,837
- Filed: 2002-09-12
- Published: 2003-12-11
- Earliest claimed: 2002-05-29
- Assignees: Impax Laboratories, LLC
- Inventors: Chien-Hsuan Han; Larry Hsu; Richard Ting; Charles Hsiao
- Web page: https://patentgrep.com/patent/US20030228360A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 31/195: having an amino group
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 25/16: Anti-Parkinson drugs
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated with depleted amounts of dopamine in a patient's brain tissue.

## Claims

### Claim 1

A pharmaceutical dosage form having an immediate release component and a controlled release component comprising:
a) an immediate release component comprising a ratio of carbidopa to levodopa of from about 1:1 to about 1:50 such that the in vitro dissolution rate of the immediate release component according to measurements under the USP paddle method of 50 rpm in 900 ml aqueous buffer at pH 4 at 37° C. is from about 10% to about 99% Levodopa released after 15 minutes and from about 60% to about 99% after 1 hour;
b) a controlled release component comprising a ratio of carbidopa to levodopa of from about 1:1 to about 1:50 such that the in vitro dissolution rate of the controlled release component according to measurements under the USP paddle method of 50 rpm in 900 ml aqueous buffer at pH 4 at 37° C. is from about 10% to about 60% levodopa released after 1 hour; from about 20% to about 80% released after 2 hours; and from about 30% to about 99% after about 6 hours, the in vitro release rate chosen such that the initial peak plasma level of levodopa obtained in vivo occurs between 0.1 and 6 hours after administration of the dosage form to a patient.

### Claim 2 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the in vitro release rate is chosen such that the initial peak plasma level of levodopa obtained in vivo occurs between 0.1 and 2 hours after administration of the dosage form to a patient.

### Claim 3 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the immediate release component comprises a ratio of carbidopa to levodopa of from about 1:1 to about 1:10.

### Claim 4 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the immediate release component comprises a ratio of carbidopa to levodopa of from about 1:1 to about 1:5.

### Claim 5 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the immediate release component comprises a ratio of carbidopa to levodopa of from about 1:1 to about 1:4.

### Claim 6 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the controlled release component comprises a ratio of carbidopa to levodopa of from about 1:1 to about 1:10.

### Claim 7 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the controlled release component comprises a ratio of carbidopa to levodopa of from about 1:1 to about 1:5.

### Claim 8 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the controlled release component comprises a ratio of carbidopa to levodopa of from about 1:1 to about 1:4.

### Claim 9 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the in vitro dissolution rate of carbidopa of the immediate release component according to measurements under the USP paddle method of 50 rpm in 900 ml aqueous buffer at pH 4 at 37° C. is from about 95% to about 99% after about 1 hour.

### Claim 10 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the controlled release component comprises from about 10 to about 200 mg of carbidopa and from 25 to about 600 mg levodopa.

### Claim 11 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the controlled release component comprises from about 25 to about 150 mg of carbidopa and from 50 to about 500 mg levodopa.

### Claim 12 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the controlled release component comprises from about 25 to about 50 mg of carbidopa and from 50 to about 200 mg levodopa.

### Claim 13 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the immediate release component comprises from about 5 to about 75 mg of carbidopa and from 25 to about 300 mg levodopa.

### Claim 14 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein some percentage of the total amount of carbidopa is replaced by another decarboxylase inhibitor.

### Claim 15 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein some or all of the Levodopa is in the form of the pro-drug 3-hydroxy-L-tyrosine ethyl ester.

### Claim 16 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the dosage form is comprised of particles.

### Claim 17 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the dosage form is comprised of a tablet.

### Claim 18 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the dosage form is comprised of a bi layer tablet.

### Claim 19 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the amount of carbidopa in the dosage form is selected from the group consisting of 12.5, 25, 50, 75 and 100 mg.

### Claim 20 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the amount of Levodopa in the dosage form is selected from the group consisting of 25, 37.5, 50, 70, 75, 80, 100, 125, 130, 150, 200, 250, 300, and 400 mg.

### Claim 21 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the total amount of Carbidopa to Levodopa in the dosage form is 50 mg/100 mg with the Carbidopa to Levodopa amount in the immediate release portion being 25 mg/50 mg and the Carbidopa to Levodopa amount in the controlled release portion being 25 mg/70 mg.

### Claim 22 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the total amount of Carbidopa to Levodopa in the dosage form is 50 mg/150 mg with the Carbidopa to Levodopa amount in the immediate release portion being 25 mg/70 mg and the Carbidopa to Levodopa amount in the controlled release portion being 25 mg/80 mg.

### Claim 23 (depends on 1)

A pharmaceutical dosage form according to claim 1 wherein the total amount of Carbidopa to Levodopa in the dosage form is 50 mg/200 mg with the Carbidopa to Levodopa amount in the immediate release portion being 25 mg/70 mg and the Carbidopa to Levodopa amount in the controlled release portion being 25 mg/130 mg.

### Claim 24

A pharmaceutical dosage form having an immediate release component and a controlled release component comprising:
a) an immediate release component comprising a ratio of carbidopa to levodopa of from about 1:1 to about 1:50 such that the in vitro dissolution rate of the immediate release component according to measurements under the USP paddle method of 50 rpm in 900 ml aqueous buffer at pH 4 at 37° C. is from about 10% to about 99% Levodopa released after 30 minutes and from about 60% to about 99% after 1 hour;
b) a controlled release component comprising a ratio of carbidopa to levodopa of from about 1:1 to about 1:50 such that the in vitro dissolution rate of the controlled release component according to measurements under the USP paddle method of 50 rpm in 900 ml aqueous buffer at pH 4 at 37° C. is from about 10% to about 60% levodopa released after 1 hour; from about 20% to about 80% released after 2 hours; and from about 30% to about 99% after about 6 hours, the in vitro release rate being chosen such that the initial peak plasma level of levodopa obtained in vivo occurs between 0.1 and 6 hours after administration of the dosage form.

### Claim 25

A pharmaceutical dosage form having an immediate release component and a controlled release component comprising:
a) an immediate release composition comprising a combination of levodopa and carbidopa in the form of a coating on a solid dosage form;
b) a controlled release composition making up the solid dosage form comprising an active ingredient combination of levodopa and carbidopa together with a retarding agent of a type and amount sufficient to provide the release of active ingredient for a period of from about 1 hour to about 24 hours.

### Claim 26 (depends on 1, 21, 22)

A method of treating a patient suffering from a pathology or diseases characterized by reduced levels of dopamine in a patients brain comprising the step of administering to the patient a dosage form according to any of claims 1, 21 or 22.
